Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon

摘要

Combination of at least two direct acting antiviral agents (DAAs) for use in the treatment of hepatitis C (HCV) in a patient, wherein the treatment includes administration of ribavirin but does not include administration of interferon, wherein the at least two DAAs comprise PSI-7977 (sofosbuvir, GS-7977) and TMC-435 (simeprevir), and wherein the treatment lasts for no more than about 12 weeks. The treatment may further include administration of ritonavir or another CYP3A4 inhibitor. The at least two DDAs may be administered concurrently, sequentially or may be co-formulated in a single composition. Preferably the patient is a treatment-naive patient infected with HCV genotype 1. Preferably PSI-7977 is administered in a daily dosage of 100mg to 500mg and preferably TMC-435 is administered in a daily dosage of 25 to 250mg.